BioSpace News Archive

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15. Dr. Fruchtman and Avi Oler, Senior VP, Corporate Development, will be available for 1x1 meetings scheduled through t

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today that clinical data from its NeuroStar Outcomes Registry, which suggests NeuroStar Advanced Therapy be evaluated as a first-line treatment for Major Depressive Disorder (MDD), will be published in the December 2020

InMode Ltd. (Nasdaq: INMD ), a leading global provider of innovative medical technologies, announced today that it will release its financial results for the third quarter 2020 before the Nasdaq market opens on T

BioTalent Canada today released new findings from its most recent bio-economy Labour Market Information (LMI) study. The data in this new brief— The Talent Differential: The case for work-integrated learning in the bio-economy —was collected from a series of three facilitated roundtable discussions, a survey of 573 bio-economy employers in 2020, and an analysis of data from BioTalent Canada’s current wage subsidy progra

NantHealth , Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, presented virtually with NantOmics and ImmunityBio on September 29-30 2020, a session entitled “ Deep-learning image-based tumor, stroma and lymphocytes spatial relationships and clinical featu

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will host a Twist Biopharma Analyst & Investor Event on Friday, October 23, 2020. The event is scheduled to take place from 11:00 a.m. – 1:00 p.m. ET in a virtual format. The event will include an overview of Twist

Gamida Cell and Be The Match BioTherapies ® Expand Strategic Collaboration – Organizations to work together to integrate Be The Match BioTherapies’ existing cell therapy infrastructure to manage the supply chain for potential commercialization of omidubicel –

Valeo Pharma Inc., a Canadian specialty pharmaceutical company, announced that it has commenced shipping online orders of its unique flavonoid formulation, HespercoTM.

Data from the first clinical study of IONIS-ENAC-2.5 Rx to be presented at North American Cystic Fibrosis Conference

Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies